Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

263.24 -6.85 (-2.54%)

Streaming Delayed Price Updated: 3:30 PM EDT, Sep 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why. ↗

April 20, 2023

So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the...

Via Benzinga

NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S ↗

April 17, 2023

San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND

April 14, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 12, 2023

Via Benzinga

Why Ascendis Pharma Stock Is Crashing This Week ↗

April 06, 2023

The FDA put a roadblock in the path to market for Ascendis' hypoparathyroidism drug.

Via The Motley Fool

Analyst Ratings for Ascendis Pharma ↗

April 03, 2023

Via Benzinga

Why Ascendis Pharma Stock Is Plunging Today ↗

April 03, 2023

A regulatory hiccup is weighing on the biopharma's shares today.

Via The Motley Fool

Ascendis Pharma Flags Regulatory Delay In US For Its Hypoparathyroidism Candidate ↗

April 03, 2023

Via Benzinga

ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm

April 07, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023 ↗

April 05, 2023

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation

April 04, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Analyst Expectations for Ascendis Pharma's Future ↗

February 03, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗

April 04, 2023

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

April 04, 2023

From The Schall Law Firm

Via Business Wire

Where Ascendis Pharma Stands With Analysts ↗

November 29, 2022

Via Benzinga

What 9 Analyst Ratings Have To Say About Ascendis Pharma ↗

November 29, 2022

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

April 03, 2023

From The Schall Law Firm

Via Business Wire

Nasdaq Down 80 Points; VirTra Shares Spike Higher ↗

April 03, 2023

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping around 80 points on Monday. The Dow traded up 0.89% to 33,571.43 while the NASDAQ fell 0.66% to 12,142.07. The S&P...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 03, 2023

Via Benzinga

Dow Up Triple Digits As Second Quarter Kicks Off ↗

April 03, 2023

The Dow Jones Industrial Average is up 146 points midday to kick off the second quarter, while the S&P 500 Index inches lower, and the Nasdaq Composite sits firmly in the red.

Via Talk Markets

Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 03, 2023

Gainers Nogin, Inc. (NASDAQ: NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 101% to $14.24 after climbing 50% on Friday.

Via Benzinga

Crude Oil Jumps Over 6%; OncoSec Medical Shares Plummet ↗

April 03, 2023

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. The Dow traded up 0.58% to 33,468.38 while the NASDAQ fell 0.96% to 12,104.67. The...

Via Benzinga

Tesla, NIO And Other Big Stocks Moving Lower On Monday ↗

April 03, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug Application ↗

April 03, 2023

The FDA decision prevents Ascendis from labeling and marketing the new drug application for TransCon PTH. ASND stock plunged

Via Investor's Business Daily

ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND

April 03, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 03, 2023

Via Benzinga

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study ↗

March 06, 2023

The company is testing a drug for children with achondroplasia, a cause of dwarfism.

Via Investor's Business Daily

Johnson & Johnson: Taking The Bull By The Horns?

February 21, 2023

Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.

Via MarketBeat

Topics Intellectual Property Regulatory Compliance

Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices ↗

January 14, 2023

Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

All News about Ascendis Pharma A/S - Ordinary Share